Q-omics provides the consensus-scored NRIP2 profile across patient tissues and cancer cell-line models. NRIP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, NRIP2 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, NRIP2 protein abundance shows 29,365 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight PAAD, KIRP, and GBM as cancer lineages where NRIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRIP2 survival associations across molecular data types. NRIP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRIP2 RNA expression–survival associations across cancer types. High NRIP2 expression shows unfavorable associations in UVM, but favorable associations in PAAD, KIRC, LUAD, UCEC and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for NRIP2 RNA expression.
This table summarizes NRIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NRIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRIP2 shows lower tumor expression in KIRP, THCA, KICH, LUAD and BLCA and higher tumor expression in LIHC. The KIRP box plot shows higher NRIP2 RNA expression in normal versus tumor tissue (log2 FC = −1.746, t-test p < 0.001).
This table shows molecular features associated with NRIP2 in patient tissues and cancer cell lines. In patient samples, NRIP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
